Urothelial Cancer

The addition of atezolizumab to neoadjuvant gemcitabine and cisplatin generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival and overall survival in patients with muscle-invasive bladder cancer, according to data from a phase 2 trial.

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

Second-line sacituzumab govitecan plus pembrolizumab generated promising antitumor activity in patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

Niraparib in combination with cabozantinib demonstrated a manageable safety profile, with preliminary efficacy observed in heavily pretreated patients with metastatic urothelial carcinoma.

Daniel P. Petrylak, MD, discusses the utilization of enfortumab vedotin-ejfv in patients with muscle-invasive bladder cancer (MIBC).

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.

Avelumab failed to demonstrate an improvement in overall survival at 1 year as frontline treatment in patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer, though it did elicit a notable objective response rate.

The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.

The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.

Jonathan A. Chatzkel, MD, discusses the future treatment options in bladder cancer.

Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.

Expert reflection on the current unmet needs in metastatic urothelial carcinoma and hope for future improvements in the treatment armamentarium.

Following frontline maintenance therapy in metastatic urothelial carcinoma, Ignacio Duran, MD, PhD, considers optimal second-line treatment options.

The novel non-viral gene therapy, EG-70, produced a complete response rate of 83% at 3 months in evaluable patients with high-grade non–muscle invasive bladder cancer with carcinoma in situ who were unresponsive to Bacillus Calmette-Guérin.

Ali R. Khaki, MD, comments on how to treat patients with advanced bladder cancer based on data demonstrated by the EV-103 study of enfortumab vedotin.

Ali R. Khaki, MD, describes the impact of the EV-103 study of enfortumab vedotin in advanced bladder cancer.

UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.

Dr Benjamin Miron highlights data specific to treating patients with relapsed metastatic disease.

Bradley McGregor, MD, reacts to treatment advances for advanced bladder cancer and shares perspective on utilizing newer, novel therapies as the field continues to evolve

Clinical pearls of advice regarding the optimal management of metastatic urothelial carcinoma in today’s treatment landscape.

Expert perspectives on novel treatment approaches being investigated in the second-line setting of metastatic urothelial carcinoma and beyond.

Practical advice on maintenance therapy in metastatic urothelial carcinoma, covering patient education, duration of therapy, and clinical guidelines.

A review of the JAVELIN Bladder 100 trial, which evaluated avelumab maintenance therapy following frontline chemotherapy in metastatic urothelial carcinoma.